Nucor earnings beat by $0.08, revenue fell short of estimates
In a recent transaction, Sadie Stern (AS:PBHP), Executive Vice President and Chief Human Resources Officer at Dexcom Inc. (NASDAQ:DXCM), sold 11,176 shares of the company’s common stock. The shares were sold on March 12 at an average price of $70.38 per share, totaling approximately $786,567.
This sale was part of a mandatory transaction to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs), as required by Dexcom’s equity incentive plans. Following the sale, Stern retains direct ownership of 115,805 shares, which includes 74,450 unvested restricted stock units. These units are set to vest in stages through March 2028.
In other recent news, DexCom reported fourth-quarter earnings that fell short of analyst expectations, with adjusted earnings per share at $0.45 compared to the anticipated $0.52. However, revenue for the quarter reached $1.11 billion, slightly surpassing the $1.1 billion forecast and marking an 8% year-over-year increase. For the full year 2024, the company achieved an 11% growth in revenue, totaling $4.03 billion, with U.S. revenue up 10% and international revenue rising 15%. Looking forward, DexCom projects 2025 revenue of approximately $4.6 billion, which is slightly below the consensus estimate of $4.61 billion.
In another development, BTIG analysts maintained their Buy rating for DexCom despite a warning letter from the FDA regarding manufacturing processes and quality management system deficiencies. This letter followed inspections of DexCom’s facilities, but the company assured that it would not impact production or financial projections. Meanwhile, Bernstein analysts raised their price target for DexCom to $100, citing a return to stability and a positive revenue forecast for 2025. Additionally, DexCom announced the appointment of Renée Galá to its Board of Directors, bringing her extensive experience in financial and strategic leadership from Jazz Pharmaceuticals (NASDAQ:JAZZ). These recent developments paint a complex picture of DexCom’s current position in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.